Lymphocyte News and Research

RSS

When CDK12/13 stalls, healthy prostate cells take a malignant turn

CDK12 is established as a tumor suppressor in prostate cancer, with its loss driving aggressive disease and creating vulnerabilities for targeted therapies.

7 Oct 2024

Salt can boost antitumor responses of T cells

Elevated sodium levels in tumors boost T-cell metabolic fitness and cytotoxicity, revealing potential avenues for improving cancer therapies.

13 Sep 2024

Study identifies key predictors of severe mpox cases

The study uncovers factors influencing mpox severity and duration, emphasizing the role of viral load and specific clinical presentations in patient outcomes.

2 Sep 2024

New targets for improved cancer immunotherapy

In the past two decades, immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, showing promising results against various solid tumors. This study reviews recent developments in ICIs, focusing on new targets like T cell immunoreceptors with Ig and ITIM domains (TIGIT), T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3), and lymphocyte activation gene-3 (LAG-3). These targets aim to overcome resistance mechanisms limiting the effectiveness of current therapies, such as anti-PD-1 and anti-CTLA-4. By identifying and developing these new ICIs, researchers hope to improve treatment outcomes and provide new therapeutic options for cancer patients.

14 Aug 2024

Exploring the distinct characteristics of Nodular Lymphocyte Predominant Hodgkin Lymphoma

This review offers an in-depth exploration of Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL), highlighting its distinct characteristics across various domains such as epidemiology, clinical presentation, histopathology, immunophenotype, genetic findings, and challenges in differential diagnosis.

13 Aug 2024

Review of fasting-mimicking diets in cancer treatment

Researchers present the role of cyclic fasting and fasting-mimicking diets (FMD) in cancer therapy.

8 Aug 2024

New research uncovers mechanisms behind heart damage from CTLA-4 blockade

Cytotoxic T-lymphocyte antigen 4 (CTLA-4) is a protein receptor on T immune cells that prevents the cells from killing other cells, such as cancer cells.

7 Aug 2024

Cellular competition determines X chromosome usage in female bodies

A new study published in Nature Genetics by the Lymphoid Development Group at the MRC Laboratory of Medical Sciences has reveals that the contribution of cells expressing maternal or paternal X chromosomes can be selectively skewed in different parts of the body. The study leverages human data from the 1000 Genomes Project combined with mouse models of human X chromosome-linked DNA sequence variation to advance our fundamental understanding of development in biologically female individuals who have two X chromosomes.

26 Jul 2024

Simple blood test may predict CAR-T therapy success in multiple myeloma

A simple blood test that measures the number of lymphocytes, a type of white blood cell in the body, may predict whether people who have relapsed multiple myeloma are going to respond well to CAR-T immunotherapy, according to new research from Weill Cornell Medicine, NewYork-Presbyterian, Columbia University and Icahn School of Medicine at Mount Sinai.

24 Jul 2024

FDA approval of lifileucel: A milestone in tumor-infiltrating lymphocyte therapy for advanced melanoma

The recent U.S. Food and Drug Administration approval of lifileucel, the first commercial tumor-infiltrating lymphocyte (TIL) therapy for advanced melanoma, marks a significant breakthrough in cancer therapy.

18 Jul 2024

Triad of immune cells key to successful cancer immunotherapy, study finds

There's a frustrating fact about today's immunotherapies for cancer. While sometimes they work beautifully -; completely eliminating or greatly reducing cancer in particular patients -; other times they don't work at all. It's a mystery.

15 Jul 2024

Cellular immunotherapy offers hope for solid tumors

Early findings from a small clinical trial provide evidence that a new cellular immunotherapy approach may be effective in treating metastatic solid tumors. In the trial, researchers from the National Institutes of Health (NIH) genetically engineered normal white blood cells, known as lymphocytes, from each patient to produce receptors that recognize and attack their specific cancer cells.

12 Jul 2024

deCODE genetics study highlights potential drug targets for autoimmune thyroid disease

Scientists at deCODE genetics, a subsidiary of Amgen, have published a study in Nature Communications, comparing over 110 thousand patients with autoimmune thyroid disease (AITD) from Iceland, Finland, UK and USA with 1,1 million controls.

11 Jul 2024

How does SARS-CoV-2 cause lymphopenia when T cells barely express ACE-2 receptors?

Researchers reveal both direct and indirect mechanisms of SARS-CoV-2-induced lymphopenia, highlighting the role of CD147 and alternative viral entry routes into T cells.

8 Jul 2024

Breakthrough humanized mouse model offers new insights for immunotherapy development

A breakthrough for biomedical research promises new insight into immunotherapy development and disease modeling.

5 Jul 2024

Advancements in immunotherapy for hepatocellular carcinoma offer hope to patients

Hepatocellular carcinoma (HCC) is a primary liver cancer predominantly arising from chronic liver diseases such as hepatitis B and C infections, alcohol abuse, and metabolic disorders.

2 Jul 2024

Fibrinogen-like protein 1 plays dual role in liver regeneration and hepatocellular carcinoma recurrence

Hepatocellular carcinoma (HCC), a leading cause of cancer-related mortality globally, exhibits a dismal five-year survival rate of only 18%.

2 Jul 2024

Study reveals laboratory predictors of periprosthetic joint infection in morbidly obese patients

For patients with severe obesity undergoing knee or hip replacement, commonly obtained laboratory values – including markers of anemia and inflammation – are independent predictors of the risk of periprosthetic joint infection (PJI), reports a study in The Journal of Bone & Joint Surgery.

1 Jul 2024

Regulatory T cells exist as large, mobile population that travels through body to repair damaged tissue

Researchers investigated populations of regulatory T cells, a type of white blood cell, in various tissues.